Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Isoniazid Methanesulfonate
2. Methaniazide
3. Methaniazide, Sodium Salt
4. Neoiscotin
1. Neoiscotin
2. Methaniazide Sodium
3. 3804-89-5
4. Isoniazid Methanesulfonate Sodium
5. Neo-tizide Sodium Salt
6. Neotizide Sodium Salt
7. Sodium Isoniazid Methanesulfonate
8. Sodium Methanesulfonate Isoniazid
9. 7sz6s9m7ig
10. Isonicotinic Acid, 2-(sulfomethyl)hydrazide Monosodium Salt
11. Sodium;[2-(pyridine-4-carbonyl)hydrazinyl]methanesulfonate
12. Nsc-81103
13. Ncgc00181167-01
14. Einecs 223-275-0
15. Nsc 81103
16. Unii-7sz6s9m7ig
17. 2'-(sulphomethyl)isonicotinohydrazide, Monosodium Salt
18. Sodium Isonicotinyl Hydrazine Methansulfonate
19. Isonicotinic Acid Hydrazide Methane Sulfonate (van)
20. Isonicotinsaeur-hydrazid-methansulfonsaeuren Natrium [german]
21. Isonicotinic Acid, 2-(sulfomethyl)hydrazide, Sodium Salt
22. 4-pyridinecarboxylic Acid, 2-(sulfomethyl)hydrazide, Monosodium Salt
23. Dsstox_cid_26885
24. Dsstox_rid_81988
25. Dsstox_gsid_46885
26. Isonicotinsaeur-hydrazid-methansulfonsaeuren Natrium
27. Chembl3187762
28. Dtxsid7046885
29. Tox21_112768
30. Methaniazide Sodium [who-dd]
31. Akos033878769
32. Cas-3804-89-5
33. Isoniazid Methanesulfonate Sodium [mi]
34. Sodium Isonicotinylhydrazide Methanesulfonate
35. Q27268806
36. Sodium [(pyridin-4-yl)formohydrazido]methanesulfonate
37. Z2373906036
| Molecular Weight | 253.21 g/mol |
|---|---|
| Molecular Formula | C7H8N3NaO4S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 253.01332120 g/mol |
| Monoisotopic Mass | 253.01332120 g/mol |
| Topological Polar Surface Area | 120 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 310 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
A Neoiscotin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neoiscotin, including repackagers and relabelers. The FDA regulates Neoiscotin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neoiscotin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Neoiscotin supplier is an individual or a company that provides Neoiscotin active pharmaceutical ingredient (API) or Neoiscotin finished formulations upon request. The Neoiscotin suppliers may include Neoiscotin API manufacturers, exporters, distributors and traders.
click here to find a list of Neoiscotin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Neoiscotin Drug Master File in Japan (Neoiscotin JDMF) empowers Neoiscotin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Neoiscotin JDMF during the approval evaluation for pharmaceutical products. At the time of Neoiscotin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Neoiscotin suppliers with JDMF on PharmaCompass.
Neoiscotin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neoiscotin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Neoiscotin GMP manufacturer or Neoiscotin GMP API supplier for your needs.
A Neoiscotin CoA (Certificate of Analysis) is a formal document that attests to Neoiscotin's compliance with Neoiscotin specifications and serves as a tool for batch-level quality control.
Neoiscotin CoA mostly includes findings from lab analyses of a specific batch. For each Neoiscotin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neoiscotin may be tested according to a variety of international standards, such as European Pharmacopoeia (Neoiscotin EP), Neoiscotin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neoiscotin USP).
LOOKING FOR A SUPPLIER?
